Cargando…

Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia

Post-remission strategies for patients with acute lymphoblastic leukemia (ALL) are limited to the multiagent chemotherapy and allogeneic stem cell transplant (allo-SCT), and cellular therapies are seldom involved. Although chemotherapy combined with mismatched granulocyte colony-stimulating factor m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Bo, Wang, Yi, Lei, Yangyang, Shi, Yanping, Sun, Qiyun, Qiao, Jianhui, Hu, Kaixun, Lei, Yaqing, Li, Bingxia, Liu, Tieqiang, Liu, Zhiqing, Yao, Bo, Zhao, Xuecong, Li, Xiaofei, Zhao, Wen, Feng, Xiujie, Xie, Anli, Ning, Xin, Feng, Mingxing, Zhao, Weiwei, Guo, Jiayue, Ai, Huisheng, Yu, Changlin, Guo, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Human Clinical Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672851/ https://www.ncbi.nlm.nih.gov/pubmed/36181762 http://dx.doi.org/10.1093/stcltm/szac066

Ejemplares similares

Mismatched donor cell infusion-related syndrome following microtransplant in patients with acute myeloid leukemia
por: Cai, Bo, et al.
Publicado: (2023)

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
por: Cai, Bo, et al.
Publicado: (2016)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL
por: Yu, Changlin, et al.
Publicado: (2020)

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
por: Peddada, Krishi, et al.
Publicado: (2018)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
por: Jalaeikhoo, Hasan, et al.
Publicado: (2018)

Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia
por: Tran, Phu Ngoc, et al.
Publicado: (2017)

The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma
por: Reed, Allison, et al.
Publicado: (2019)

Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
por: Malakoutikhah, Zahra, et al.
Publicado: (2023)

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
por: Sonnevi, Kristina, et al.
Publicado: (2021)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
por: Abla, Dima, et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
por: DeRon, Nathan, et al.
Publicado: (2022)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Progression of a hepatosplenic gamma delta T‐cell leukemia/lymphoma on hyperCVAD/MTX and ara‐C: literature review and our institutional treatment approach
por: Saste, Abhijit, et al.
Publicado: (2015)

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
por: Li, Chun, et al.
Publicado: (2020)

Severe acute radiation syndrome: treatment of a lethally (60)Co-source irradiated accident victim in China with HLA-mismatched peripheral blood stem cell transplantation and mesenchymal stem cells
por: Guo, Mei, et al.
Publicado: (2014)

Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy
por: Law, Man Fai, et al.
Publicado: (2021)

Hyper-CVAD/MA方案与CHALL-01方案治疗60岁以下成人Ph阳性急性淋巴细胞白血病的疗效分析
Publicado: (2019)

Outcomes of both abbreviated hyper‐CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10‐year single‐centre experience with literature review
por: Alwasaidi, Turki Abdulaziz, et al.
Publicado: (2015)

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG
por: Linder, Katherine, et al.
Publicado: (2016)

Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL
por: Marín-Sánchez, Alberto, et al.
Publicado: (2021)

Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
por: Simon, Arne, et al.
Publicado: (2008)

Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021;5(20):3913-3918.
Publicado: (2022)

Hyper-Null Models and Their Applications
por: Zeng, Yujie, et al.
Publicado: (2023)

Central Venous Access Devices (CVAD) in Pediatric Oncology Patients—A Single-Center Retrospective Study Over More Than 9 Years
por: Beck, Olaf, et al.
Publicado: (2019)

The hyper-activation of transcriptional enhancers in breast cancer
por: Li, Qing-Lan, et al.
Publicado: (2019)

Natural Melanin-Based Nanoparticles With Combined Chemo/Photothermal/Photodynamic Effect Induce Immunogenic Cell Death (ICD) on Tumor
por: Liu, Ding, et al.
Publicado: (2021)

Polysaccharides From Pogostemon cablin (Blanco) Benth.: Characterization and Antioxidant Activities
por: Zhao, Lei, et al.
Publicado: (2022)

Groundwater Depths Affect Phosphorus and Potassium Resorption but Not Their Utilization in a Desert Phreatophyte in Its Hyper-Arid Environment
por: Zhang, Bo, et al.
Publicado: (2021)

Hyper IgE syndrome
por: Dang, Yun, et al.
Publicado: (2014)

MicroRNAs: Mediators and Therapeutic Targets to Airway Hyper Reactivity After Respiratory Syncytial Virus Infection
por: Feng, Shuwen, et al.
Publicado: (2018)

Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice
por: Zhao, Bingxia, et al.
Publicado: (2017)

Engineering Corynebacterium glutamicum for violacein hyper production
por: Sun, Hongnian, et al.
Publicado: (2016)

X-linked hyper-IgM syndrome with eosinophilia in a male child: A case report
por: GUO, LI, et al.
Publicado: (2015)

Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP)
por: Guo, Weihong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_58atu43cd8u1q5g992nr2njf90